#USA #New York #Faruqi & Faruqi #MoonLake #MLTX

Faruqi & Faruqi Issues Reminder for MoonLake Investors

In a recent announcement, Faruqi & Faruqi, LLP, a prominent national securities law firm, has drawn attention to the impending class action lawsuit involving MoonLake (NASDAQ: MLTX). Investors who purchased or acquired securities in the company between March 10, 2024, and September 29, 2025, are reminded of the crucial lead plaintiff deadline on December 15, 2025.

The firm is currently investigating potential claims against Reuters Research Inc., the parent company of MoonLake, due to multiple allegations surrounding the company’s transparency and communication regarding its products. Investors are encouraged to reach out to Faruqi & Faruqi partner Josh Wilson for further discussion regarding their legal rights and possible options.

Background of the Case

Landmark allegations against MoonLake include that the company's executives failed to disclose significant information regarding their product differences. For instance, the allegations pinpoint that the company made misleading claims about the effectiveness of its product SLK in comparison to traditional monoclonal antibodies, like BIMZELX.

Specifically, reports suggest that:
1. Both SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F.
2. SLK's unique Nanobody structure does not offer any clinical advantage over the existing monoclonal structure of BIMZELX.
3. Assumptions made about SLK's supposed superior tissue penetration falling short of proving clinical efficacy.
4. Given these points, the positive assertions made by the defendants about SLK’s superiority were unsubstantiated.

Impact on Investors

On September 28, 2025, the results from MoonLake's Phase 3 VELA program were announced, showcasing disappointing findings concerning SLK’s efficacy in comparison to BIMZELX. Following this disclosure, MoonLake's market position plummeted dramatically, causing its stock to lose almost 90% of its value overnight, falling from approximately $61.99 to a mere $6.24 per share. This unexpected downward spiral severely impacted the financial standing of many investors.

As the deadline for pursuing lead plaintiff status approaches, it is essential for affected investors to act swiftly. The role of the lead plaintiff is paramount, as this individual will oversee the class action litigation on behalf of fellow investors. Participants in the class can also choose to remain absent and will not negatively impact their share in any potential recoveries, regardless of their decision to become lead plaintiffs or not.

Contact Information

Faruqi & Faruqi is keen to connect with anyone who possesses information relating to MoonLake’s operations, including former employees or whistleblowers, to strengthen the case. Those seeking to learn more about the ongoing situation or to get involved in the class action can visit Faruqi & Faruqi's dedicated page for further details.

To discuss claims or concerns, callers can reach Josh Wilson directly at: 877-247-4292 or 212-983-9330 (Ext. 1310).

The legal team at Faruqi & Faruqi, founded in 1995, has an impressive history of recovering hundreds of millions for investors across various sectors, confirming their strong commitment to justice for clients. Follow their updates on platforms such as LinkedIn, X, or Facebook as this case unfolds.